Aegerion Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Aegerion Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

Aegerion Pharmaceuticals: 11 sponsored US clinical trials, none currently recruiting.

Aegerion Pharmaceuticals sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Homozygous Familial Hypercholesterolemia, with 1 trials.

Top-decile sponsor footprint

Aegerion Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED Phase 4

Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

NCT04026178
COMPLETED Phase 1

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

NCT02080468
COMPLETED Phase 1

Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.

NCT02080455
COMPLETED Phase 3

Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

NCT00943306
COMPLETED Phase 2

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

NCT00690443
COMPLETED Phase 3

A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

NCT00730236
COMPLETED Phase 2

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

NCT00559962
COMPLETED Phase 2

AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia

NCT00474240
COMPLETED Phase 2

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

NCT00405067
COMPLETED Phase 2

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
COMPLETED Phase 2

Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor

NCT01556906

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 6
Phase 3 2
Phase 4 1

Therapeutic Areas

Homozygous Familial Hypercholesterolemia 1
Hypercholesterolemia 1
Hyperlipidemia 1
Healthy 1

How the Aegerion Pharmaceuticals early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 11 completed (100%).

Phase mix: 3 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Homozygous Familial Hypercholesterolemia (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Aegerion Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Aegerion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Aegerion PharmaceuticalsAderans Research InstituteAllena PharmaceuticalsAOBiomeArmata Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Aegerion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aegerion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aegerion Pharmaceuticals page

11 registered trials is a research-attention snapshot, not an endorsement of Aegerion Pharmaceuticals or any single study.

  • None of Aegerion Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Homozygous Familial Hypercholesterolemia is the condition Aegerion Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Homozygous Familial Hypercholesterolemia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Aegerion Pharmaceuticals pipeline card: 11 registered trials from official public datasets.Report a data error.